Ligand sells off cancer products in restructuring

Ligand Pharmaceuticals has sold a line of cancer drugs to Eisai for $205 million, a day after announcing a separate deal for Avinza. The deal covers Ligand's four approved products--Ontak, Targretin capsules, Targretin gel and Panretin gel--and related assets. "We have now sold our two commercial operations for total cash consideration of $518 million. With the sale of our commercial operations, Ligand will become a dynamic and highly-specialized R&D and royalty company," said Henry F. Blissenbach, Ligand chairman and CEO. "By the end of 2006, Ligand expects to have new corporate leadership, to have restructured and narrowly focused its research and development endeavors in order to focus on our most promising compounds, and to minimize its expense structure with a goal to be both earnings and cash-flow positive."

- check out the AP report on the deal

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.